Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-re… Recruiting

2024-516650-22-00 Renal carcinoma 6 2025-05-16
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Non-Small Cell Lung Cancer 5 2025-05-14
A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer Recruiting

2024-516615-25-00 hepatocellular carcinoma (HCC) 1 2025-05-14
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity Recruiting

2023-506260-14-00 multiple myeloma 4 2025-05-13
A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, b… Recruiting

2024-519498-20-00 Acute Myeloid Leukaemia (AML)/higher-risk Myelodysplast 9 2025-05-13
zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting

2023-509598-22-01 Oncology - Breast cancer 6 2025-05-13
Unravelling the local and systemic effects of primary surgery and perioperative use of ketorolac and pregabalin in primary breast cancer pat… Recruiting

2023-507440-36-00 Estrogen receptor-positive early breast cancer (ER + BC 4 2025-05-12
A Study of Duvelisib Versus the Anti-cancer Drugs Gemcitabine or Bendamustine in Patients With T Cell lymphoma (a type of blood cancer), whi… Recruiting

2024-516605-23-00 relapsed/refractory nodal T cell lymphoma with T follic 5 2025-05-12
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi… Recruiting

2024-515593-27-00 relapsed or refractory mantle cell lymphoma (R/R MCL) 5 2025-05-08
COSENSE-1: A feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemot… Recruiting

2024-517677-25-00 MSS/pMMR metastatic colorectal cancer 4 2025-05-07
Lu177-Dotatate every 16 weeks to reduce adverse events in patients with midgut neuroendocrine tumors Recruiting

2024-517921-14-00 Neuroendocrine tumors of midgut origin 9 2025-05-07
A study to evaluate the benefit of adding durvalumab after chemotherapy, durvalumab and surgery in patients with early-stage, operable, non-… Recruiting

2023-508773-82-00 Stage IIB-IIIB (N2) resectable non small cell lung canc 5 2025-05-06
Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs). Recruiting

2024-511915-21-01 advanced or metastasic triple-negative breast cancer 1 2025-05-05
Clinical trial for the use of a humanized CART directed against BCMA (ARI0002h) in patients with newly diagnosed primary plasma cell leukemi… Recruiting

2024-515053-21-00 Plasma cell leukaemia 4 2025-04-30
Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer? Recruiting

2024-511435-10-00 Hepatocellular Carcinoma 1 2025-04-30
Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub… Recruiting

2024-510893-25-00 Brain metastases of cancer > brain radionecrosis 5 2025-04-29
A First-in-Human Study to Test the Safety and Effects of the Investigational Drug IPH4502 in People with Advanced Cancers Recruiting

2024-519162-46-00 Advanced Solid Tumors 1 2025-04-25
Sequential Gilteritinib in Combination with Venetoclax and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mut… Recruiting

2023-507878-41-00 Acute myeloid leukemia 4 2025-04-25
Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Dur… Recruiting

2024-516367-80-00 resectable and borderline resectable stage IIIA/B NSCLC 4 2025-04-24
Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing morbid curative sur… Recruiting

2024-516152-17-00 Cutaneous squamous cell carcinoma 4 2025-04-24
Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting

2024-514465-18-00 Advanced or Metastatic Non-Squamous NSCLC 9 2025-04-23
SURVIVE HERoes – A randomized Secondary Adjuvant Treatment Intervention study comparing Trastuzumab-Deruxtecan to SOC therapy in eBC Patient… Recruiting

2024-516173-76-01 HER2-positive or HER2-low (incl. ultra-low) early breas 5 2025-04-22
A phase II study of Sonidegib in Nevoid Basal Cell Carcinoma Syndrome (Gorlin) syndrome and sporadic BCC patients in EADO stage IIb. SIBLING… Recruiting

2024-515989-14-00 Nevoid Basal Cell Carcinoma Syndrome 4 2025-04-17
A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting

2024-515279-37-00 Relapsed or Refractory and Lenalidomide exposed Multipl 5 2025-04-17